Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
D 51.59 -1.43% -0.75
BMY closed down 1.43 percent on Monday, March 18, 2024, on 1.14 times normal volume.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Volume Surge Other -1.43%
Down 3 Days in a Row Weakness -1.43%
Hammer Candlestick Bullish -1.71%
Slingshot Bullish Bullish Swing Setup -1.71%
Doji - Bullish? Reversal -1.71%
Slingshot Bullish Bullish Swing Setup -2.01%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 19 hours ago
Fell Below Previous Day's Low about 20 hours ago
Down 1% about 20 hours ago
Fell Below 20 DMA about 20 hours ago
2x Volume Pace 4 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bristol-Myers Squibb Company Description

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Diabetes Cancer Treatment Clinic Pharmaceutical Products Hypertension Melanoma Schizophrenia Hepatitis B Multiple Myeloma Rheumatoid Arthritis Stroke Dystrophy Epidermal Growth Factor Receptor Depressive Disorder Hepatitis C Immunodeficiency Hepatitis C Virus Organic Chemistry Diabetic Nephropathy Hepatitis B Virus Atrial Fibrillation Interferon Biopharmaceutical Products Treatment Of Diabetes Chronic Myeloid Leukemia Heart Attack Hepatitis C Virus Infection Metastatic Melanoma Transplant Rejection Treatment Of Hypertension Kidney Transplant Leptin Lipodystrophy

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 68.9315
52 Week Low 47.58
Average Volume 17,364,024
200-Day Moving Average 55.27
50-Day Moving Average 50.62
20-Day Moving Average 51.92
10-Day Moving Average 53.01
Average True Range 1.13
RSI (14) 49.49
ADX 37.74
+DI 26.52
-DI 17.80
Chandelier Exit (Long, 3 ATRs) 51.64
Chandelier Exit (Short, 3 ATRs) 52.23
Upper Bollinger Bands 54.56
Lower Bollinger Band 49.28
Percent B (%b) 0.44
BandWidth 10.16
MACD Line 0.70
MACD Signal Line 0.77
MACD Histogram -0.0695
Fundamentals Value
Market Cap 104.97 Billion
Num Shares 2.03 Billion
EPS 3.86
Price-to-Earnings (P/E) Ratio 13.37
Price-to-Sales 2.25
Price-to-Book 4.49
PEG Ratio 0.67
Dividend 2.31
Dividend Yield 4.48%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.35
Resistance 3 (R3) 53.52 53.11 53.05
Resistance 2 (R2) 53.11 52.66 53.02 52.95
Resistance 1 (R1) 52.35 52.39 52.15 52.18 52.86
Pivot Point 51.94 51.94 51.84 51.85 51.94
Support 1 (S1) 51.18 51.49 50.98 51.01 50.32
Support 2 (S2) 50.77 51.22 50.68 50.23
Support 3 (S3) 50.01 50.77 50.13
Support 4 (S4) 49.84